Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Lund, Kaja ^a   Dembinski, Jennifer L ^a,d   Solberg, Nina ^a   Urbanucci, Alfonso ^b,c   Mills, Ian G ^b,c   Krauss, Stefan ^a  

^a Cancer Stem Cell Innovation Centre   (Norway)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; FLUOROURACIL; NERVE CELL ADHESION MOLECULE L1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SLUG; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ARTICLE; CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LONG TERM CARE; MICROARRAY ANALYSIS; MOLECULAR CLONING; PANCREATIC CANCER CELL LINE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN INTERACTION; UPREGULATION; APOPTOSIS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEURAL CELL ADHESION MOLECULE L1; PANCREATIC NEOPLASMS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84929493691     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123684     Document Type: Article

References (54)

1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011 Aug 13378 (9791):607-20.
2. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003 May 3(5):330-8. PMID: 12724731
3. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000 Nov 18(4):299-313. PMID: 11081567
4. Uchibori K, Kasamatsu A, Sunaga M, Yokota S, Sakurada T, Kobayashi E, et al. Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. Int J Oncol 2012 Apr 40(4):1005-10. doi: 10.3892/ijo.2011.1300 PMID: 22179686
5. Harada K, Ferdous T, Ueyama Y. Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes. Int J Oncol 2014 Apr 44(4):1302-8. doi: 10.3892/ijo.2014.2270 PMID: 24452635
6. Zhang W, Feng M, Zheng G, Chen Y, Wang X, Pen B, et al. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochem Biophys Res Commun 2012 Jan 13417(2):679-85.
7. Hoshino H, Miyoshi N, Nagai K, Tomimaru Y, Nagano H, Sekimoto M, et al. Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer. Biochem Biophys Res Commun 2009 Dec 18390(3):1061-5. doi: 10.1016/j.bbrc.2009.10.117 PMID: 19861116
8. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009 Jul 1569(14):5820-8. doi: 10.1158/0008-5472.CAN-08-2819 PMID: 19584296
9. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002 Jun 2 (6):442-54. PMID: 12189386
10. Ginnebaugh KR, Ahmad A, Sarkar FH. The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer. Expert Opin Ther Targets 2014 Apr 23.
11. Rathjen FG, Schachner M. Immunocytological and biochemical characterization of a new neuronal cell surface component (L1 antigen) which is involved in cell adhesion. EMBO J 1984 Jan 3(1):1-10. PMID: 6368220
12. Raveh S, Gavert N, Ben-Ze'ev A. L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett 2009 Sep 18282(2):137-45.
13. Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martinez E, et al. The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol 2012 Oct 14(10):715-20. doi: 10.1007/s12094-012-0866-3 PMID: 22911547
14. Geismann C, Arlt A, Bauer I, Pfeifer M, Schirmer U, Altevogt P, et al. Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. Int J Oncol 2011 Jan 38(1):257-66. PMID: 21109948
15. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol 2010 Apr 220(5):551-61. doi: 10.1002/path.2673 PMID: 20077528
16. Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, et al. L1CAM: a major driver for tumor cell invasion and motility. Cell Adh Migr 2012 Jul 6(4):374-84. doi: 10.4161/cam.20832 PMID: 22796939
17. Kiefel H, Bondong S, Pfeifer M, Schirmer U, Erbe-Hoffmann N, Schafer H, et al. EMT-associated upregulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-kappaB activation. Carcinogenesis 2012 Oct 33(10):1919-29. doi: 10.1093/carcin/bgs220 PMID: 22764136
18. Tischler V, Pfeifer M, Hausladen S, Schirmer U, Bonde AK, Kristiansen G, et al. L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Mol Cancer 2011 10:127. doi: 10. 1186/1476-4598-10-127 PMID: 21985405
19. Ben QW, Wang JC, Liu J, Zhu Y, Yuan F, Yao WY, et al. Positive expression of L1-CAM is associated with perineural invasion and poor outcome in pancreatic ductal adenocarcinoma. Ann Surg Oncol 2010 Aug 17(8):2213-21. doi: 10.1245/s10434-010-0955-x PMID: 20162456
20. Bergmann F, Wandschneider F, Sipos B, Moldenhauer G, Schniewind B, Welsch T, et al. Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol Rep 2010 Oct 24(4):909-15. PMID: 20811670
21. Tsutsumi S, Morohashi S, Kudo Y, Akasaka H, Ogasawara H, Ono M, et al. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. J Surg Oncol 2011 Jun 1103(7):669-73. doi: 10.1002/jso.21880 PMID: 21360711
22. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995 Apr 155(7):1407-12.
23. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995 May 1749(10):1419-26.
24. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004 Feb 122(3):529-36.
25. De IS, De PA, Stocco G, Bartoli F, Bussani R, Decorti G. ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer. Anticancer Res 2008 Nov 28 (6B):3921-8. PMID: 19192650
26. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, PerryWIII, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 2005 May 4(5):855-63. PMID: 15897250
27. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000 Jun 160(11):2805-9. PMID: 10850418
28. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 2001 Mar 2095 (2):92-5.
29. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007 Dec 14(12):3629-37. PMID: 17909916
30. Tentes IK, Schmidt WM, Krupitza G, Steger GG, Mikulits W, Kortsaris A, et al. Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620. Experimental Cell Research 2010 Nov 15316(19):3172-81.
31. Kikuta K, Masamune A, Watanabe T, Ariga H, Itoh H, Hamada S, et al. Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells. Biochem Biophys Res Commun 2010 Dec 17403(3-4):380-4.
32. Bichat F, Mouawad R, Solis-Recendez G, Khayat D, Bastian G. Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line. Anticancer Res 1997 Sep 17(5A):3393-401. PMID: 9413178
33. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 Jan 7100(1):57-70.
34. Geismann C, Arlt A, Bauer I, Pfeifer M, Schirmer U, Altevogt P, et al. Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. Int J Oncol 2011 Jan 38(1):257-66. PMID: 21109948
35. Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 2006 Jan 1566(2):936-43.
36. Min JK, Kim JM, Li S, Lee JW, Yoon H, Ryu CJ, et al. L1 cell adhesion molecule is a novel therapeutic target in intrahepatic cholangiocarcinoma. Clin Cancer Res 2010 Jul 1516(14):3571-80. doi: 10.1158/ 1078-0432.CCR-09-3075 PMID: 20501614
37. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, et al. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res 2008 Feb 1568(4):1110-8.
38. Sebens MS, Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene 2007 Apr 2626(19):2759-68.
39. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005 Feb 14168(4):633-42.
40. Geismann C, Morscheck M, Koch D, Bergmann F, Ungefroren H, Arlt A, et al. Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer. Cancer Res 2009 May 1569(10):4517-26. doi: 10.1158/0008-5472.CAN-08-3493 PMID: 19435915
41. Pfeifer M, Schirmer U, Geismann C, Schafer H, Sebens S, Altevogt P. L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC Mol Biol 2010 11:64. doi: 10.1186/1471-2199-11-64 PMID: 20799950
42. Pan JJ, Yang MH. The role of epithelial-mesenchymal transition in pancreatic cancer. J Gastrointest Oncol 2011 Sep 2(3):151-6. doi: 10.3978/j.issn.2078-6891.2011.022 PMID: 22811845
43. Blauwkamp TA, Nigam S, Ardehali R, Weissman IL, Nusse R. Endogenous Wnt signalling in human embryonic stem cells generates an equilibrium of distinct lineage-specified progenitors. Nat Commun 2012 3:1070. doi: 10.1038/ncomms2064 PMID: 22990866
44. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997 Jun 15(6):2403-13. PMID: 9196156
45. Seufferlein T, Bachet JB, Van CE, Rougier P. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012 Oct 23 Suppl 7:vii33-vii40. PMID: 22997452
46. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 May 12364(19):1817-25.
47. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010 Sep 8304(10):1073-81. doi: 10.1001/jama.2010.1275 PMID: 20823433
48. Shtutman M, Levina E, Ohouo P, Baig M, Roninson IB. Cell adhesion molecule L1 disrupts E-cadherincontaining adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res 2006 Dec 166(23):11370-80.
49. Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP, et al. The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 2008 Feb 2127(9):1281-9.
50. Novak-Hofer I, Cohrs S, Grunberg J, Friedli A, Schlatter MC, Pfeifer M, et al. Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells. Cancer Lett 2008 Mar 18261(2):193-204.
51. Gavert N, Vivanti A, Hazin J, Brabletz T, Ben-Ze'ev A. L1-mediated colon cancer cell metastasis does not require changes in EMT and cancer stem cell markers. Mol Cancer Res 2011 Jan 9 (1):14-24. doi: 10.1158/1541-7786.MCR-10-0406 PMID: 21123622
52. Sebens S, Schafer H. The Adhesion Molecule L1CAM as a Novel Therapeutic Target for Treatment of Pancreatic Cancer Patients? In: Prof.Srivastava Sanjay, editor. Pancreatic Cancer- Molecular Mechanism and Targets. InTech; 2012. p. 329-44.
53. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010 May 2838(4):576-89.
54. Dembinski JL, Krauss S. A Distinct Slow-Cycling Cancer Stem-like Subpopulation of Pancreatic Adenocarcinoma Cells is maintained in Vivo. Cancers 2010 Nov 292(4):2011-25.